Happy Tuesday, D.C. Diagnosis readers! We are just a week away from Election Day, and I’m sure you’re all feeling the anticipation building. If you have any news, tips, or feedback on the election coverage, feel free to send them to [email protected]. Also, keep an eye out for a special DCD edition from my colleague John Wilkerson coming your way tomorrow.
Over the weekend, former President Trump made headlines with some interesting comments. During a lengthy interview with podcaster Joe Rogan and a rally at Madison Square Garden, Trump discussed his political priorities, particularly in the realm of healthcare. One key point he touched on was the involvement of Robert F. Kennedy Jr. in his potential second administration. Trump expressed his intention to let RFK Jr. take charge of health, food, and medicines, which has sparked concern among many, including former GOP officials and industry executives.
While Trump seems to be supportive of RFK Jr.’s role, he did address the topic of vaccine safety with caution during his interview with Rogan. Trump acknowledged the importance of vaccines like the polio vaccine, highlighting the positive impact they have had on public health.
This endorsement of RFK Jr. by Trump hints at potential healthcare policies in a future Trump administration. From possible ACA reform to addressing high drug prices, there are a number of actions Trump might take if he were to be reelected.
In another vein, Trump’s discussions on genetics, particularly in relation to undocumented immigrants, have brought attention to the resurgence of the eugenics movement in the U.S. Experts note a growing emphasis on genetic determinism and race science, fueled in part by the popularity of genetic sequencing companies offering insights into our genetic backgrounds.
On the healthcare front, Medicare Director Meena Seshamani sheds light on the process of negotiating drug prices under the Inflation Reduction Act. She shares insights from her private sector experience, patient meetings, and stakeholder consultations that shaped the new prices for top-selling drugs in America. Looking ahead, CMS is gearing up for a second round of negotiations, with plans to announce up to 15 drugs for the next cycle by February 1st.
Meanwhile, the debate over the Dietary Guidelines for Americans is heating up once again, with an advisory panel meeting to discuss key issues like ultra-processed foods, alcohol, added sugar, and saturated fat. The outcome of these discussions could have significant implications for the health and well-being of many Americans.
Despite the wealth of topics in the healthcare and policy arena, STAT’s First Opinion editor, Torie Bosch, reveals a surprising gap in opinion pieces on the health of major presidential candidates. While her inbox is filled with submissions on various topics, very few experts are willing to tackle this particular subject. Torie explores the reasons behind this reluctance and shares her insights on the matter.
As we navigate through these complex and critical issues in health and medicine, it’s essential to stay informed and engaged. Keep an eye on upcoming developments in healthcare policy and be proactive in advocating for the well-being of all individuals.
